Enable JavaScript to visit this website.

Already received the first dose of TRUMENBA?

Ensure your teen completes all recommended doses of TRUMENBA to help protect them against MenB.

Home

trumenba-vaccine

TRUMENBA is a vaccine for meningococcal group B disease (also known as MenB)1

TRUMENBA is FDA approved to help protect your teen against this disease.1

MenB is an uncommon but potentially deadly disease that can lead to death within 24 hours.2,3

Talk to your doctor or pharmacist about vaccinating your teen with TRUMENBA today.

TRUMENBA helps protect your teen when they need it most4,5

In adolescents and young adults, the incidence of MenB peaks at age 19, so if your teen is between 16 and 23, they may be at increased risk.5

TRUMENBA is a MenB vaccine clinically studied in the United States. Patients in the TRUMENBA clinical trials were adolescents and young adults.1

Talk to your doctor or pharmacist about whether or not your teen is protected against MenB.

trumenba help
vaccine

Your teen may not be protected

There are 5 primary types of bacteria that cause meningococcal disease and for which vaccines are available in the US: A, C, W, Y, and B.6

The Centers for Disease Control and Prevention (CDC) recommends vaccination for types A, C, W, and Y at ages 11 to 12, and a booster at age 16. The CDC-preferred age for MenB vaccination is 16 to 18 years.7,8

Even if your teen already received a vaccine for meningococcal disease (MCV4), which covers meningitis A, C, W, and Y, they may not be protected against MenB.8

pharmacy icon

Want to know where you can get TRUMENBA near you?

Find a location
locator icon
Already received the first dose of TRUMENBA?

Get text reminders for the next dose.

Enroll now
IMPORTANT SAFETY INFORMATION
  • Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
  • Some individuals with weakened immune systems may have a reduced immune response
  • Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections
  • Fainting can occur in association with administration of injectable vaccines, including Trumenba
  • The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your health care provider if you are pregnant, or plan to become pregnant
  • Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child
INDICATION
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed
Call 1-844-TRUMENBA (878-6362), 9 AM to 7 PM ET, Monday through Friday, for more information.

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

This product information provided in this site is intended only for residents of the United States. The products discussed in this site may have different product labeling in different countries.

The health information in this site is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

REFERENCES
  1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc; 2018.
  2. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  3. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607.
  4. Patton ME, Stephens D, Moore K, et al. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine–Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509-513.
  5. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: a report by the National Foundation for Infectious Diseases. http://www.nfid.org/meningococcal-b. Published May 2014. Accessed August 21, 2018.
  6. McNeil LK, Zagursky RJ, Lin SL, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77(2):234-252.
  7. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger. UNITED STATES, 2019. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Updated February 22, 2019. Accessed March 27, 2019.
  8. MacNeil JR, Rubin L, Folaranmi T. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171-1176.
Back to top